iPath*D / Cancer / Depression · Interventional Study

Developing and Testing an Online Pathway From Screening to Treatment for Depression in Oncology: iPath*D (Aim 2)

ClinicalTrials.gov · August 7, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registry record for an ongoing, single-arm feasibility study of an online depression screening and treatment pathway (iPath*D) in oncology patients. No results have been posted; the study is designed to evaluate usability, acceptability, and feasibility outcomes at 2, 4, and 6 weeks, with no efficacy or clinical outcome data reported.

What was studied

Interventional, Single Group, Open label, Other purpose. Cancer, Depression; age from 18 Years. Intervention: iPath*D. n = 30. 1 site: United States.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This feasibility study cannot yet inform clinical practice, as no results are available. Once completed, it may support or refine implementation of an online depression screening pathway in oncology settings, pending demonstration of acceptable usability and feasibility.

Plain-language summary

This is an active, uncontrolled feasibility and usability study with no published results; it measures acceptability and system usability in a small planned sample, typical of early-stage implementation research.

Study design

As stated by the source record.

MethodsPrimary outcome measures: System usability (assessed at 2 weeks); Acceptability of intervention (assessed at 2 weeks); Feasibility of intervention (assessed at 2 weeks); Change in number of patients selecting a treatment path to access (assessed at 2 weeks, 4 weeks, 6 weeks); Change in Mental Health Literacy (MHL) (assessed at Baseline, 2 weeks)

DesignInterventional, Single Group, Open label, Other purpose

PopulationCancer, Depression; age from 18 Years

Sample size30

InterventioniPath*D

Setting1 site: United States

Reported figures

Quoted from the source exactly as published.

Planned enrollment30

Primary outcome: System usability2 weeks

Primary outcome: Acceptability of intervention2 weeks

Primary outcome: Feasibility of intervention2 weeks

Secondary outcome: Change in number of patients selecting treatment path2 weeks, 4 weeks, 6 weeks

Secondary outcome: Mental Health Literacy changeBaseline, 2 weeks

Clinical bottom line

Caveats

No results posted; this is a registry record only, not a published study with outcomes.
Single-arm design with no control or comparator group; no efficacy or clinical effectiveness data will be generated.
Small sample size (30 planned); appropriate for feasibility but limits generalizability.
Primary outcomes are process measures (usability, acceptability, feasibility), not clinical outcomes such as depression symptom reduction or treatment uptake.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Single-arm, uncontrolled feasibility study with no comparator reported.

Directness

moderate

Measures usability and acceptability directly; no clinical outcomes or treatment efficacy reported.

Consistency

insufficient

No results posted; consistency cannot be assessed from registry record alone.

Risk of bias

insufficient

Registry record does not detail methods, allocation, or blinding; methodological detail unavailable.

Sample adequacy

limited

Planned enrollment of 30 participants; adequate for feasibility but underpowered for efficacy.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT05302375). This is a study registration, not published results. Lead sponsor: Dartmouth-Hitchcock Medical Center. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 30 participants (ESTIMATED). Conditions: Cancer, Depression. Interventions: OTHER: iPath*D. Primary outcome measures: System usability , 2 weeks; Acceptability of intervention , 2 weeks; Feasibility of intervention , 2 weeks; Change in number of patients selecting a treatment path to access , 2 weeks, 4 weeks, 6 weeks; Change in Mental Health Literacy (MHL) , Baseline, 2 weeks. Brief summary: The purpose of this study is to determine the extent to which an online pathway to depression treatment (iPath\*D) is acceptable and usable to patients receiving cancer treatment who report symptoms of depression.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

iPath*DCancerDepressionDartmouth-Hitchcock Medical CenterNCT05302375